Rising Australian biotech stars set to connect on the world stage

March 30, 2008

Two of Australia's leading life scientists have been chosen from a highly competitive field of candidates to take part in an initiative by Merck Sharp & Dohme and Advance to boost the capability of the country's burgeoning biopharmaceutical industry.

Antisense Therapeutics Ltd (ASX code: ANP) Research Director Dr Christopher Wraight and DendriMed Research Director Dr Raisa Monteiro have been selected as joint winners of the 2008 Advancing BioBusiness Award, which aims to expand vital global connections for Australian science and foster more international business for local life sciences companies.

They will attend the world's largest biotechnology meeting, the Biotechnology Industry Organisation (BIO) international convention in San Diego in June, which attracts over 22,000 visitors.

A tailored program of meetings will also be scheduled with leading American organisations and individuals including venture capital firms, research institutes, biotechnology entrepreneurs and biopharmaceutical companies. This will help build valuable international networks, knowledge and collaborations that will benefit their business and the Australian industry.

The Advancing BioBusiness Award is an innovative scheme by Merck Sharp & Dohme and Advance, a dynamic, diverse global community of Australian professionals overseas committed to advancing Australia and Australians.

Senator Kim Carr, Minister for Innovation, Industry, Science and Research, said:

"The Advancing BioBusiness Award complements the Rudd Government's policy of promoting innovation and commercialisation in the biotechnology and pharmaceutical sector, encouraging closer links between Australian biotech and global pharmaceutical companies, and helping Australian biotechs access global supply chains."

Dr Phil Kearney, Merck Sharp & Dohme's manager for external scientific affairs, said Australia is recognised for its excellence in medical research and its vigorous and creative biopharmaceutical industry. However the number of drug development projects which reach advanced clinical development is only a quarter of what would be predicted on the basis of our output in scientific literature.

"By immersing two of our top biopharmaceutical people in successful commercial research centres in the United States, and providing them with opportunities to share their learning back at home, we aim to build a stronger Australian capability to win in this highly competitive global knowledge market," he said.
-end-


Research Australia

Related Biotechnology Articles from Brightsurf:

Cyanobacteria as "green" catalysts in biotechnology
Researchers from TU Graz and Ruhr University Bochum show in the journal ACS Catalysis how the catalytic activity of cyanobacteria, also known as blue-green algae, can be significantly increased.

Biotechnology to the rescue of Brussels sprouts
An international team has identified the genes that make these plants resistant to the pathogen that attacks crops belonging to the cabbage family all over the world.

UM professor co-authors report on the use of biotechnology in forests
University of Montana Professor Diana Six is one of 12 authors of a new report that addresses the potential for biotechnology to provide solutions for protecting forest trees from insect and pathogen outbreaks, which are increasing because of climate change and expanded global trade.

Faster genome evolution methods to transform yeast for industrial biotechnology
A research team led by Prof. DAI Junbiao at the Shenzhen Institutes of Advanced Technology (SIAT) of the Chinese Academy of Sciences, in collaboration with Prof.

New innovations in cell-free biotechnology
Professor Michael Jewett's new platform to conduct cell-free protein synthesis could lead to improved quality of manufactured protein therapeutics and biomaterials.

Silk 'micrococoons' could be used in biotechnology and medicine
Microscopic versions of the cocoons spun by silkworms have been manufactured by a team of researchers.

The end of biotechnology as we know it
More than 400 attendees from five continents discussed trends and improvements in biotechnology at the European Summit of Industrial Biotechnology (ESIB) in Graz/Austria and talked many topics like a dehumanized research process.

Biotechnology: A growing field in the developing world
A detailed new report surveys a broad cross-section of biotechnology work across developing countries, revealing steady growth in fields tied to human well-being worldwide.

China releases first report on biotechnology in developing countries
The first report on biotechnology in developing countries revealing an overall picture of their biotechnology growth and competitiveness was released on Nov.

Exclusive: Biotechnology leaders surveyed about impact of Trump presidency
The day following the election of Donald J. Trump as President, a survey of leaders in biotechnology in the United States, conducted by Genetic Engineering & Biotechnology News showed that Trump's presidency will negatively impact NIH research funding as well as STEM education; a plurality said it will also spark a 'brain drain' as foreign-born researchers educated in American universities will be more likely to leave.

Read More: Biotechnology News and Biotechnology Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.